ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes

FRIDAY, June 12, 2026-- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose...